课题基金 / 基金详情

Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases

Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases
SARS-CoV-2 3CL 和 PL 蛋白酶的定制过渡态类似物抑制剂
批准号:
429694
负责人:
Strynadka Natalie C
金额:
$29.36万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2020
资助国家:
加拿大
项目状态:
已结题
起止时间:
2020-05-01 至 2021-05-01

项目摘要

项目成果

Strynadka Natalie C的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SARS-CoV-2 is devastating global health and economies. Rapid development of antiviral drugs is critical to treat disease in the short term and beyond. Logical antiviral targets are the proteases 3CLpro and PLpro, responsible for processing of long chains
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
  • 批准号:
    480022
  • 项目类别:
    Operating Grants
  • 资助金额:
    $90.56万
  • 财政年份:
    2023
  • 负责人:
    Strynadka Natalie C
  • 依托单位:
COVID-19 Variant Supplement - Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases
  • 批准号:
    443277
  • 项目类别:
    Operating Grants
  • 资助金额:
    $3.64万
  • 财政年份:
    2021
  • 负责人:
    Strynadka Natalie C
  • 依托单位:
COVID-19 Variant Network - Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases
  • 批准号:
    443340
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Strynadka Natalie C
  • 依托单位:
Structure-guided in vitro and in situ analysis of virulence linked secretion systems in drug-resistant bacteria
  • 批准号:
    452796
  • 项目类别:
    Operating Grants
  • 资助金额:
    $90.56万
  • 财政年份:
    2021
  • 负责人:
    Strynadka Natalie C
  • 依托单位:
海外基金